Richard C O'Brien

US Patent:

7831490, Nov 9, 2010

Filed:

Feb 26, 2004

Appl. No.:

10/786023

Inventors:

Franco Modigliani - Cambridge MA, US
Serena Modigliani, legal representative - Cambridge MA, US
Richard James O'Brien - Lisle IL, US
Francis M. Vitagliano - Boston MA, US

Assignee:

Payment Pathways, Inc. - Chicago IL

International Classification:

G06Q 40/10

US Classification:

705 35

Abstract:

The present invention relates to a central (root) directory and/or network of directories to linked credit accounts. Each linked credit account accepts, or is responsive to incoming payments or credits, without the need for access numbers, account numbers, routing numbers, or the like. The payment/deposit account may be set up as a deposit only account (e. g. , it cannot pay out or be debited in the traditional sense). In this way, it can be effective in eliminating many of the security requirements of a traditional financial account.

US Patent:

8252572, Aug 28, 2012

Filed:

Feb 18, 2010

Appl. No.:

12/708441

Inventors:

John C. Hutton - Denver CO, US
Richard O'Brien - Brentwood TN, US
Howard Davidson - Denver CO, US
Seija Hackl - Aurora CO, US

International Classification:

C12N 9/00
C07K 14/00

US Classification:

435183, 514 1

Abstract:

A method and compositions for detecting autoimmunity to islet glucose-6-phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD), insulin and insulin granule membrane proteins ICA512 (IA-2) and phogrin (IA2β) auto-antigens, provides an effective and reliable chemical assay for the diagnosis of autoimmune (type 1) diabetes. Additionally, this invention provides therapeutic regimens based on IGRP and related molecules for the amelioration of the diabetic clinical condition. Therefore, IGRP alone or in combination with other autioimmune diabetes associated antigens such as insulin, IA-2 and GAD, is useful in the prediction (diagnosis), treatment (therapy), and prevention (prophylaxis) of diabetes.

US Patent:

20070203059, Aug 30, 2007

Filed:

Sep 20, 2004

Appl. No.:

10/573280

Inventors:

John Hutton - Denver CO, US
Richard O'Brien - Brentwood TN, US
Howard Davidson - Denver CO, US
Seija Hackl - Aurora CO, US

International Classification:

A61K 38/22
G01N 33/53

US Classification:

514012000, 435007100

Abstract:

A method and compositions for detecting autoimmunity to islet glucose-6 phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD), insulin and insulin granule membrane proteins ICA512 (IA-2) and phogrin (IA-2) auto-antigens, provides an effective and reliable chemical assay for the diagnosis of autoimmune (type 1) diabetes. Additionally, this invention provides therapeutic regimens based on IGRP and related molecules for the amelioration of the diabetic clinical condition. Therefore, IGRP alone or in combination with other autoimmune diabetes associated antigens such as insulin, IA-2 and GAD, is useful in the prediction (diagnosis), treatment (therapy), and prevention (prophylaxis) of diabetes.

US Patent:

20120321648, Dec 20, 2012

Filed:

Aug 23, 2012

Appl. No.:

13/593443

Inventors:

John C. Hutton - Denver CO, US
Richard O'Brien - Brentwood TN, US
Howard Davidson - Denver CO, US
Seija Hackl - Aurora CO, US

International Classification:

A61K 39/00
A61P 37/06
A61P 3/10
C07K 14/435
G01N 33/53

US Classification:

4241841, 530350, 435 792

Abstract:

A method and compositions for detecting autoimmunity to islet glucose-6-phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD), insulin and insulin granule membrane proteins ICA512 (IA-2) and phogrin (IA2β) auto-antigens, provides an effective and reliable chemical assay for the diagnosis of autoimmune (type 1) diabetes. Additionally, this invention provides therapeutic regimens based on IGRP and related molecules for the amelioration of the diabetic clinical condition. Therefore, IGRP alone or in combination with other autoimmune diabetes associated antigens such as insulin, IA-2 and GAD, is useful in the prediction (diagnosis), treatment (therapy), and prevention (prophylaxis) of diabetes.

US Patent:

D4162080, Nov 9, 1999

Filed:

Jul 2, 1998

Appl. No.:

D/090257

Inventors:

Michael D. Arney - Needham MA
David P. Chastain - Acton MA
Joseph R. Geringer - Melrose MA
Richard O'Brien - Waltham MA
John C. Costello - Wellesley MA
Ronald G. Wood - Mechanicsville VA
Kevin R. Young - Brighton MA

Assignee:

AMF Bowling Inc. - Mechanicsville VA

International Classification:

2101

US Classification:

D10 461

US Patent:

46213112, Nov 4, 1986

Filed:

Feb 6, 1985

Appl. No.:

6/698799

Inventors:

Richard A. O'Brien - Newton MA

Assignee:

Stevens-Arnold, Inc. - Boston MA

International Classification:

H02M 3335

US Classification:

363 21

Abstract:

A pulse-width modulation, switching DC-to-DC convertor uses positive feedback to combine the conventional comparator and state latch functions. The combined comparator/latch circuit reduces propagation delays through the circuitry and allows operation at higher frequencies. In place of the conventional serially-connected comparator, latch and output transistor, a high-speed comparator is modified by using positive feedback to convert it into a latching comparator. The duty cycle of the output transistor is controlled by the logical combination of the output of an internal oscillator and the output of the latching comparator. The latching comparator is controlled by an error signal and a signal representative of the current running through the output transistor thereby eliminating the usual ramp generation circuitry.